Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 24, 2019
Daily News
December 24, 2019
- 930 Million Yen Allocated for Amended PMD Law-Related Projects: MHLW Pharma Safety Bureau
December 24, 2019
- Towa to Acquire Spanish Generic Player, Set to Venture into US/European Markets
December 24, 2019
- Eisai’s Insomnia Drug Grabs US Approval, Japan Nod Expected Soon
December 24, 2019
- US FDA Accepts Resubmission for Sunovion’s Parkinson’s Med
December 24, 2019
- Boehringer’s Thorsten Poehl Named as New EFPIA Japan Chief
December 24, 2019
- Promethera to Launch Japan Trial of Cell Therapy Targeting ACLF by FY2021
December 24, 2019
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
December 24, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…